Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)

ClinicalTrials.gov ID: NCT02580058

Public ClinicalTrials.gov record NCT02580058. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 9:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF AVELUMAB (MSB0010718C) ALONE OR IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN ALONE IN PATIENTS WITH PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A Phase 3 global study comparing avelumab alone to avelumab plus PLD and to PLD alone to demonstrate that avelumab given alone or in combination with PLD is superior to PLD alone in prolonging Overall Survival in patients with platinum resistant/platinum refractory ovarian cancer.

Study identification

NCT ID
NCT02580058
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Pfizer
Industry
Enrollment
566 participants

Conditions and interventions

Conditions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Dec 21, 2015 (Actual)
Primary completion
Sep 19, 2018 (Actual)
Completion
Jul 12, 2022 (Actual)
Last update posted
Jul 10, 2023

2015 – 2022

United States locations

U.S. sites
87
U.S. states
22
U.S. cities
57
Facility City State ZIP Site status
Arizona Oncology Associates, PC - HAL Chandler Arizona 85224 —
Arizona Oncology Associates, PC - HAL Phoenix Arizona 85016 —
Arizona Oncology Associates, PC - HAL Phoenix Arizona 85027 —
Arizona Oncology Associates, PC - HAL Scottsdale Arizona 85258 —
Arizona Oncology Associates, PC-HAL Tempe Arizona 85284 —
Arizona Oncology Associates, PC - HOPE Tucson Arizona 85704 —
Arizona Oncology Associates, PC - HOPE Tucson Arizona 85711 —
Highlands Oncology Group Fayetteville Arkansas 72703 —
Highlands Oncology Group Rogers Arkansas 72758 —
University of California, Irvine/UC Irvine Health Orange California 92868 —
Sansum Clinic Santa Barbara California 93105 —
Sansum Clinic Solvang California 93463 —
Rocky Mountain Cancer Centers Aurora Colorado 80012 —
Rocky Mountain Cancer Centers Boulder Colorado 80303 —
Rocky Mountain Cancer Centers Lakewood Colorado 80228 —
Florida Cancer Specialists Daytona Beach Florida 32117 —
Florida Cancer Specialists Wellington Florida 33414 —
Florida Cancer Specialists West Palm Beach Florida 33401 —
Atlanta Gynecologic Oncology Atlanta Georgia 30342 —
Northside Hospital - Pharmacy Atlanta Georgia 30342 —
University Gynecologic Oncology Atlanta Georgia 30342 —
Northwest Georgia Oncology Centers, P.C. Austell Georgia 30106 —
Northwest Georgia Oncology Centers, P.C. Carrollton Georgia 30117 —
Northwest Georgia Oncology Centers, P.C. Cartersville Georgia 30121 —
Northwest Georgia Oncology Centers, P.C. Douglasville Georgia 30134 —
Northwest Georgia Oncology Centers, P.C. Marietta Georgia 30060 —
The University of Kansas Clinical Research Center Fairway Kansas 66205 —
The University of Kansas Cancer Center and Medical Pavilion Westwood Kansas 66205 —
Norton Cancer Institute, Norton Healthcare Pavilion Louisville Kentucky 40202 —
Norton Healthcare Pharmacy, Attn: Marlon Baranda, Pharm D Louisville Kentucky 40202 —
Norton Hospital Louisville Kentucky 40202 —
Norton Cancer Institute, St. Matthews Campus Louisville Kentucky 40207 —
Norton Women's and Children's Hospital Louisville Kentucky 40207 —
Norton Brownsboro Hospital Louisville Kentucky 40241 —
Norton Cancer Institute, Brownsboro Hospital Campus Louisville Kentucky 40241 —
Maryland Oncology Hematology, P.A. Bethesda Maryland 20817 —
Maryland Oncology Hematology, P.A. Columbia Maryland 21044 —
Maryland Oncology Hematology P.A. Silver Spring Maryland 20902 —
Maryland Oncology Hematology P.A. Silver Spring Maryland 20904 —
Massachusetts General Hospital Boston Massachusetts 02114 —
Brigham Women's Hospital Boston Massachusetts 02115 —
Dana Farber Cancer Institute Boston Massachusetts 02215 —
The University of Kansas Cancer Center, CCP - North Kansas City Missouri 64154 —
Center of Hope at Renown Regional Medical Center Reno Nevada 89502 —
Southwest GYN Oncology Associates, Inc. Albuquerque New Mexico 87106 —
University of New Mexico Comprehensive Cancer Center Albuquerque New Mexico 87106 —
Hope Women's Cancer Centers Asheville North Carolina 28806 —
Mission Hospital, Inc. Asheville North Carolina 28806 —
Novant Health Oncology Specialists Kernersville North Carolina 27284 —
Novant Health Oncology Specialists Winston-Salem North Carolina 27103 —
Cleveland Clinic Taussig Cancer Center Cleveland Ohio 44106 —
Fairview Hospital Moll Pavilion Cancer Center Cleveland Ohio 44111 —
Fairview Hospital Moll Pavilion Pharmacy Cleveland Ohio 44111 —
Cleveland Clinic Taussig Cancer Center Cleveland Ohio 44195 —
Cleveland Clinic Cleveland Ohio 44195 —
Hillcrest Hospital Hirsch Cancer Center Pharmacy Mayfield Heights Ohio 44124 —
Hillcrest Hospital Mayfield Heights Ohio 44124 —
Willamette Valley Cancer Institute and Research Center Eugene Oregon 97401 —
Investigational Drug Services, University of Pennsylvania Philadelphia Pennsylvania 19104 —
The University of Pennsylvania Health System Philadelphia Pennsylvania 19104 —
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 —
Tennessee Oncology, PLLC Dickson Tennessee 37055 —
Tennessee Oncology, PLLC Franklin Tennessee 37067 —
Tennessee Oncology, PLLC Gallatin Tennessee 37066 —
Tennessee Oncology, PLLC Hermitage Tennessee 37076 —
Tennessee Oncology, PLLC Lebanon Tennessee 37090 —
Tennessee Oncology, PLLC Murfreesboro Tennessee 37129 —
Tennessee Oncology, PLLC Nashville Tennessee 37203 —
The Sarah Cannon Research Institute Nashville Tennessee 37203 —
Tennessee Oncology, PLLC Nashville Tennessee 37205 —
Tennessee Oncology, PLLC Nashville Tennessee 37207 —
Tennessee Oncology, PLLC Nashville Tennessee 37211 —
Tennessee Oncology, PLLC Shelbyville Tennessee 37160 —
Tennessee Oncology, PLLC Smyrna Tennessee 37167 —
Texas Oncology-Austin Central Austin Texas 78731 —
Texas Oncology-South Austin Austin Texas 78745 —
Texas Oncology - Bedford Bedford Texas 76022 —
Texas Oncology -Fort Worth Cancer Center Fort Worth Texas 76104 —
US Oncology Investigational Products Center (IPC) Irving Texas 75063 —
US Oncology Investigational Products Center Irving Texas 75063 —
Texas Oncology - San Antonio Medical Center San Antonio Texas 78240 —
Texas Oncology - The Woodlands, Gynecologic Oncology The Woodlands Texas 77380 —
Utah Cancer Specialists Salt Lake City Utah 84106 —
Carilion Clinic Gynecologic Oncology Roanoke Virginia 24016 —
Carilion Clinic Roanoke Virginia 24016 —
Froedtert and The Medical College of Wisconsin Milwaukee Wisconsin 53226 —
Froedtert Hospital Milwaukee Wisconsin 53226 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 208 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02580058, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 10, 2023 · Synced Oct 20, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02580058 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →